OncClub: Join the Chat on Trending Trials in Cancer Final results from the Phase 3 ClarIDHy trial Lively expert panel discussions featuring peer-to-peer exchanges Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

OncClub: Join the Chat on Trending Trials in Cancer Final results from the Phase 3 ClarIDHy trial Lively expert panel discussions featuring peer-to-peer exchanges Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

View More Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

Biosimilars Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Multiple Myeloma

All Oncology News

Pipeline Report

Rare Cancer Series

OncClub All Oncology News Pipeline Report Rare Cancer Series

Medical World News

Thoracic Night Live

Insights Medical World News News Network OncLive TV Peer Exchange Podcasts Rapid Readouts The Talk Thoracic Night Live

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

Giants of Cancer Care PER Events Scientific Interchanges State of the Science Summit / IPC Webinars

Oncology Fellows

Supplements And Featured Publications

All Publications

Oncology Live Oncology Fellows Supplements And Featured Publications All Publications

Interactive Tools

Learning Modules

Community Interactive Tools Learning Modules Partners Sponsored

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2021 MJH Life Sciences and OncLive. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

OncLive SOSS

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2021 MJH Life Sciences^™ and OncLive. All rights reserved.

Emerging Therapies in HER 2-Positive Metastatic Breast Cancer

EP. 1: Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

EP. 2: Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

January 11th 2020

EP. 3: Impact of the KATHERINE Trial on Early-Stage HER2+ BC

January 11th 2020

EP. 4: Early-Stage HER2+ Breast Cancer: The ATEMPT Trial

January 11th 2020

EP. 5: Overview of Neoadjuvant Therapy in HER2+ Breast Cancer

January 11th 2020

EP. 6: HER2+ BC: Selection and Management of Neoadjuvant Therapy

January 11th 2020

EP. 7: Treatment Strategies for Relapsed/Refractory HER2+ mBC

January 11th 2020

EP. 8: Unmet Needs in the Management of HER2+ mBC

January 11th 2020

EP. 9: HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates

January 11th 2020

EP. 10: HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020

<
1
2
>